HighVista Strategies’s Dyne Therapeutics DYN Stock Holding History

HighVista Strategies’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.82M	Sell	171,961 -10,968	-6%	-$204K	0.87%	37
2026 Q1	$3.32M	Buy	182,929 +123,286	+207%	+$2.13M	0.92%	34
2025 Q4	$1.17M	Buy	+59,643	New	+$1.13M	0.3%	93
2025 Q3	–	Sell	-26,324	Closed	-$251K	–	157
2025 Q2	$251K	Sell	26,324 -52,096	-66%	-$574K	0.09%	141
2025 Q1	$820K	Hold	78,420	–	–	0.32%	116
2024 Q4	$1.85M	Buy	78,420 +12,938	+20%	+$383K	0.69%	47
2024 Q3	$2.35M	Buy	+65,482	New	+$2.61M	0.81%	37
2023 Q2	–	Sell	-102,431	Closed	-$1.18M	–	141
2023 Q1	$1.18M	Hold	102,431	–	–	0.96%	30
2022 Q4	$1.19M	Hold	102,431	–	–	0.7%	37
2022 Q3	$1.3M	Sell	102,431 -139,436	-58%	-$1.6M	0.74%	37
2022 Q2	$1.66M	Buy	241,867 +73,176	+43%	+$504K	1%	32
2022 Q1	$1.63M	Buy	+168,691	New	+$1.44M	1.03%	26
2021 Q1	–	Sell	-23,760	Closed	-$499K	–	131
2020 Q4	$499K	Buy	+23,760	New	+$470K	0.32%	67

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HighVista Strategies's DYN Position: Q2 2026 in Review

HighVista Strategies reduced its Dyne Therapeutics (DYN) stake by 6% in Q2 2026, selling an estimated $204K and leaving 171,961 shares worth $3.82M. The position accounts for 0.87% of the portfolio, ranked #37.

HighVista Strategies first reported a position in DYN in Q4 2020 and has held it in 13 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

HighVista Strategies held 171,961 shares of Dyne Therapeutics worth $3.82M as of Q2 2026.
HighVista Strategies sold 10,968 Dyne Therapeutics shares in Q2 2026, an estimated $204K.
Dyne Therapeutics made up 0.87% of HighVista Strategies's portfolio in Q2 2026, its #37 holding.
HighVista Strategies first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 13 quarters since.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.